174 related articles for article (PubMed ID: 18057052)
1. Endurance shuttle walking test: responsiveness to salmeterol in COPD.
Brouillard C; Pepin V; Milot J; Lacasse Y; Maltais F
Eur Respir J; 2008 Mar; 31(3):579-84. PubMed ID: 18057052
[TBL] [Abstract][Full Text] [Related]
2. Walking exercise response to bronchodilation in mild COPD: a randomized trial.
Gagnon P; Saey D; Provencher S; Milot J; Bourbeau J; Tan WC; Martel S; Maltais F
Respir Med; 2012 Dec; 106(12):1695-705. PubMed ID: 22999808
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of dyspnoea relief and improved exercise endurance after furosemide inhalation in COPD.
Jensen D; Amjadi K; Harris-McAllister V; Webb KA; O'Donnell DE
Thorax; 2008 Jul; 63(7):606-13. PubMed ID: 18250181
[TBL] [Abstract][Full Text] [Related]
4. Improved respiratory system conductance following bronchodilator predicts reduced exertional dyspnoea.
Diba C; King GG; Berend N; Salome CM
Respir Med; 2011 Sep; 105(9):1345-51. PubMed ID: 21482091
[TBL] [Abstract][Full Text] [Related]
5. Inhaled fentanyl citrate improves exercise endurance during high-intensity constant work rate cycle exercise in chronic obstructive pulmonary disease.
Jensen D; Alsuhail A; Viola R; Dudgeon DJ; Webb KA; O'Donnell DE
J Pain Symptom Manage; 2012 Apr; 43(4):706-19. PubMed ID: 22168961
[TBL] [Abstract][Full Text] [Related]
6. Effect of fluticasone/salmeterol combination on dyspnea and respiratory mechanics in mild-to-moderate COPD.
Guenette JA; Webb KA; O'Donnell DE
Respir Med; 2013 May; 107(5):708-16. PubMed ID: 23421968
[TBL] [Abstract][Full Text] [Related]
7. Prospective validation of the endurance shuttle walking test in the context of bronchodilation in COPD.
Borel B; Pepin V; Mahler DA; Nadreau É; Maltais F
Eur Respir J; 2014 Nov; 44(5):1166-76. PubMed ID: 25186261
[TBL] [Abstract][Full Text] [Related]
8. Walking versus cycling: sensitivity to bronchodilation in chronic obstructive pulmonary disease.
Pepin V; Saey D; Whittom F; LeBlanc P; Maltais F
Am J Respir Crit Care Med; 2005 Dec; 172(12):1517-22. PubMed ID: 16166613
[TBL] [Abstract][Full Text] [Related]
9. Effect of combination treatment on lung volumes and exercise endurance time in COPD.
Magnussen H; Paggiaro P; Schmidt H; Kesten S; Metzdorf N; Maltais F
Respir Med; 2012 Oct; 106(10):1413-20. PubMed ID: 22749044
[TBL] [Abstract][Full Text] [Related]
10. Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease.
Vestbo J; Pauwels R; Anderson JA; Jones P; Calverley P;
Thorax; 2005 Apr; 60(4):301-4. PubMed ID: 15790985
[TBL] [Abstract][Full Text] [Related]
11. Effect of indacaterol on dynamic lung hyperinflation and breathlessness in hyperinflated patients with COPD.
Beeh KM; Wagner F; Khindri S; Drollmann AF
COPD; 2011 Oct; 8(5):340-5. PubMed ID: 21793716
[TBL] [Abstract][Full Text] [Related]
12. An evaluation of salmeterol in the treatment of chronic obstructive pulmonary diseases.
Gupta RK; Chhabra SK
Indian J Chest Dis Allied Sci; 2002; 44(3):165-72. PubMed ID: 12206475
[TBL] [Abstract][Full Text] [Related]
13. Does single dose salmeterol affect exercise capacity in asthmatic men?
Robertson W; Simkins J; O'Hickey SP; Freeman S; Cayton RM
Eur Respir J; 1994 Nov; 7(11):1978-84. PubMed ID: 7875268
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of acute bronchodilator reversibility in patients with symptoms of GOLD stage I COPD.
O'Donnell DE; Laveneziana P; Ora J; Webb KA; Lam YM; Ofir D
Thorax; 2009 Mar; 64(3):216-23. PubMed ID: 19052054
[TBL] [Abstract][Full Text] [Related]
15. Significance of changes in endurance shuttle walking performance.
Pepin V; Laviolette L; Brouillard C; Sewell L; Singh SJ; Revill SM; Lacasse Y; Maltais F
Thorax; 2011 Feb; 66(2):115-20. PubMed ID: 21148135
[TBL] [Abstract][Full Text] [Related]
16. [Lung function and exercise tolerance after treatment with salmeterol or ipratropium bromide in chronic obstructive pulmonary disease].
Grzanka A; Pitsch T; Krzywiecki A; Rogala B
Pol Merkur Lekarski; 2004 Sep; 17(99):208-11. PubMed ID: 15628041
[TBL] [Abstract][Full Text] [Related]
17. Use of 6-min and 12-min walking test for assessing the efficacy of formoterol in COPD.
Cazzola M; Biscione GL; Pasqua F; Crigna G; Appodia M; Cardaci V; Ferri L
Respir Med; 2008 Oct; 102(10):1425-30. PubMed ID: 18621519
[TBL] [Abstract][Full Text] [Related]
18. Detecting oxygen desaturation in patients with COPD: incremental versus endurance shuttle walking.
Sandland CJ; Morgan MD; Singh SJ
Respir Med; 2008 Aug; 102(8):1148-52. PubMed ID: 18571914
[TBL] [Abstract][Full Text] [Related]
19. Effect of 12 weeks of once-daily tiotropium/olodaterol on exercise endurance during constant work-rate cycling and endurance shuttle walking in chronic obstructive pulmonary disease.
Maltais F; O'Donnell D; Gáldiz Iturri JB; Kirsten AM; Singh D; Hamilton A; Tetzlaff K; Zhao Y; Casaburi R
Ther Adv Respir Dis; 2018; 12():1753465818755091. PubMed ID: 29439648
[TBL] [Abstract][Full Text] [Related]
20. Detecting improvements in dyspnea in COPD using a three-minute constant rate shuttle walking protocol.
Sava F; Perrault H; Brouillard C; Darauay C; Hamilton A; Bourbeau J; Maltais F
COPD; 2012 Aug; 9(4):395-400. PubMed ID: 22509905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
